Skip to main content
Fig. 5 | Cancer Nanotechnology

Fig. 5

From: Ultrasensitive bioassaying of HER-2 protein for diagnosis of breast cancer using reduced graphene oxide/chitosan as nanobiocompatible platform

Fig. 5

a The ECL signals for the possible interferences: BSA, CA-15–3, CEA (0.1 ng mL) in the presence of HER-2 and mixture of them; b the related histograms for the selectivity of the proposed protocol for HER-2 quantification; c the stability of the designed biosensor in the presence of 1 fM of HER-2 (during 8 repetitive evaluation)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us